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Atherosclerosis is a multifactorial disease triggered and sustained by different risk factors
such as dyslipidemia, arterial hypertension, diabetes mellitus, smoke, etc. Since a couple
of decades, a pivotal role for inflammation in its pathogenesis has been recognized and
proved at molecular levels, and already described in many animal models. Despite all
this knowledge, due to the complexity of the specific inflammatory process subtending
atherosclerosis and to the fact that inflammation is also a protective response against
microorganisms, no anti-inflammatory therapy has been rendered available in the
therapeutic armamentarium against atherosclerosis and vascular events till 2017 when
canakinumab in the first ad-hoc randomized clinical trial (RCT) proved for the first time that
targeting specifically inflammation lowers cardiovascular (CV) events. From the genetic
side, in the 90’s and early 2000, several genetic markers in inflammatory pathway have
been explored searching for an association with athero-thrombosis which gave seldom
consistent results. Then, in the genomic era, plenty of genetic markers covering most
of the genome have been analyzed at once without a priori information. The results
coming from genome wide association studies (GWAS) have pinpointed some loci
closed to inflammatory molecules consistently associated with atherosclerosis and CV
consequences revamping the strict link between inflammation and atherosclerosis and
suggesting some tailored target therapy. Whole-exome and whole-genome sequencing
will come soon showing new and old loci associated with atherosclerosis suggesting new
molecular targets or underlying which inflammatory pathway could be most attractive to
target for blocking atherosclerosis even in its early stages.
Keywords: atherosclerosis, inflammation, genetics, anti-inflammatory drugs, genome wide association study,
DNA sequencing
INTRODUCTION
Atherosclerosis is an inflammatory disease (Ross, 1999; Libby, 2012). Accumulation of leukocytes
in the subendothelial space is an early step in the formation of atherosclerotic lesions. Then, other
inflammatory cells follow and participate in all the processes starting from the “fatty streak” and
leading to advanced atherosclerotic lesions triggering clinical events. In particular a pivotal role has
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been recognized for monocyte-derived macrophages, which
become “foam cells,” dendritic cells, lymphocytes (both T and
B), and mast cells. Lots of adhesion molecules or receptors for
leukocytes expressed on the surface of the arterial endothelial
cell probably participate in the recruitment of leukocytes to
the nascent atheroma. Proinflammatory cytokines can act at
different stages in the process: interleukin 1 (IL-1) and tumor
necrosis factor (TNF) can regulate the expression of adhesion
molecules involved in early and late leukocyte recruitment.
Indeed, IL-1 and TNF can induce local production of growth
factors, including fibroblast growth factors (FGF) and platelet-
derived growth factor (PDGF) which attract smooth-muscle cells
from the tunica media into the intima. Finally, other cytokines
and growth factors may be important in the evolution to a
more advanced fibrous plaque which may be protective against
plaque rupture: i.e., the transforming growth factor β (TGF-β)
stimulates whereas interferon γ (IFN-γ) counteracts interstitial
collagen production by smooth-muscle cells (Ross, 1999; Libby,
2012).
C- reactive protein (CRP) is an acute phase reaction protein,
produced by the liver and triggered especially by interleukin-6
(IL-6) which is often used in the clinic as an inflammatorymarker
in “classical” inflammatory disease such as infections, vasculitis,
tumors. When all these conditions are excluded, CRP, even in the
lower range of detection, could be useful to monitor subclinical
inflammatory state deriving from atherosclerosis (Libby and
Ridker, 2004).
The Jupiter trial have already shown that patients with 2.0
mg/L or higher level of CRP benefit from statin therapy to lower
their CV risk. But of course in that trial not only CRP (by
37%) but especially LDL cholesterol decreased (nearly by 50%)
along with all the end-points: myocardial infarction (MI), stroke,
arterial revascularization, hospitalization for unstable angina, or
death from CV causes (Ridker et al., 2008). Thus, after this trial
it was still plausible that the reduced LDL-cholesterol levels and
not the reduced grade of inflammation mostly contributed to this
beneficial result.
Secretory phospholipase A2 (sPLA2) and lipoprotein-
associated phospholipase A2 (Lp-PLA2) were identified in
animal and observational studies in humans, as potential
risk factors for coronary heart disease due to their putative
effects on lipids and inflammation (Rosenson et al., 2010;
Wang et al., 2011). Nevertheless, two randomized clinical trials
(RCTs), exploring the possible efficacy of darapladib, a Lp-PLA2
inhibitor, in patients after an acute coronary syndrome (ACS)
or stable coronary atherosclerosis, did not find any difference
in CV and cerebrovascular events as compared to placebo
(O’Donoghue et al., 2014; STABILITY Investigators et al.,
2014). A RCT, testing varespladib, a sPLA2 inhibitor, failed to
demonstrate a beneficial CV effect and showed instead a possible
increase in coronary events (Nicholls et al., 2014). A genetic
variant, rs11573156 of the sPLA2 gene was associated with lower
level of sPLA2 but not with major vascular events. Thus, also
Mendelian randomization analysis fails to indicate sPLA2 as
a possible target for preventing CV diseases (Holmes et al.,
2013).
TARGETING INFLAMMATION WITH OLD
DRUGS
Beside the current large availability of anti-inflammatory drugs in
the medical field, targeting specifically inflammation in humans
remains challenging. In fact, most of available anti-inflammatory
medications have adverse effects which render their use, as a
chronic therapy to prevent CV events, not feasible and some of
them have proved to be deleterious.
Nevertheless, at least a clue can be drawn by exploring clinical
trials (which in post-hoc analyses evaluated these drugs for their
potential role in CV risk) or observational surveys related to
patients which need these drugs for other indications, such as
chronic inflammatory or degenerative diseases.
Among the anti-inflammatory therapies, the non-steroidal
anti-inflammatory drugs (NSAIDs) are the most common used
drugs worldwide in acute inflammatory disease, chronic therapy
for osteoarthritis or other painful debilitating diseases. NSAIDs
effects have been explored in many trials and their potential
CV effect evaluated many times. Quite recently, in a network
meta-analysis including 31 trials which analyzed either NSAIDs
and coxibs, both rofecoxib and lumiracoxib were associated
with an increased risk of MI whereas ibuprofen and diclofenac
with the risk of stroke.(Trelle et al., 2011) Two years later a
comprehensive meta-analysis collected 280 trials where different
anti-inflammatory agents were tested vs. placebo and 474 trials
where the comparison was between anti-inflammatory agents
and another NSAIDs (including coxibs) (Coxib and traditional
NSAID Trialists’ (CNT) Collaboration et al., 2013). Major
vascular events, and especially coronary events were increased by
coxibs, diclofenac, and ibuprofen. Only high-dose naproxen was
associated with less vascular risk than other NSAIDs (Coxib and
traditional NSAID Trialists’ (CNT) Collaboration et al., 2013).
Methotrexate (MTX) is an anti-inflammatory drug widely
used for the treatment of chronic inflammatory disorders such
as rheumatoid arthritis and psoriasis. A systematic review
and meta-analysis exploring the effect of MTX on major
CV outcomes searched for cohorts, case-control studies, and
randomized trials (Micha et al., 2011). In many observational
studies MTX was associated with lower risk for CVD (21%
reduction) and MI (18% reduction; Micha et al., 2011). The
authors suggested that MTX could be a useful drug to decrease
CV risk and these findings were in line with other meta-analyses
(Roubille et al., 2015).
About possible effects of corticosteroids, Roubille and co-
authors explored studies in patients with rheumatoid and
psoriatic arthritis. Corticosteroids were associated with an
increased risk of cardiovascular events regardless of the
inflammatory disease (Roubille et al., 2015). This was probably
due to the well-known adverse cardiometabolic effects of
this class of drugs. The same meta-analysis indicated that in
rheumatoid arthritis, TNF inhibitors can reduce the risk of CV
events. These data confirmed findings of previous meta-analyses
and large registries (Barnabe et al., 2011; Westlake et al., 2011;
Low et al., 2017) but other studies did not find any significant
difference (Ryan et al., 2011; Ljung et al., 2012).
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Thus, TNF may represent an anti-inflammatory drug for
atherosclerosis, even though its potent adverse effects and high
cost makes its use for this treatment unlikely.
Another biological therapy for chronic plaque psoriasis
targets interleukin 12 (IL-12) and interleukin 23 (IL-23). Two
meta-analyses explored their possible effect on CV risks. The
conclusion of the first meta-analysis is that anti IL-12/23 therapy
is not statistically different from placebo regarding CV events, but
it is underlined that 10 major adverse CV events were registered
in the intervention arm as compared to 0 in the placebo group.
(Ryan et al., 2011) A successive meta-analysis, including some
more trials, concluded that IL-12/23 therapy increases the risk of
a CV outcome (Tzellos et al., 2013).
In a phase II RCT 182 patients with NSTE-ACS, recruited in
the first 48 h from onset of chest pain, were allocated to either
placebo or subcutaneous IL-1 receptor antagonist (IL-1ra) for 14
days. The IL-1ra group, significantly reduced hs-CRP and IL-
6 levels (P = 0.02). The study was underpowered to detect a
difference in CV endpoints. Nevertheless, MACE despite being
similar till the 3rd month were higher in the IL-1ra group at 1
year (Morton et al., 2015).
THE CANTOS STUDY AND THE PROOF OF
CONCEPT
In September 2017, the results of the Canakinumab Anti-
inflammatory Thrombosis Outcome Study (CANTOS) trial
irrupted in the scientific field unequivocally proving for the first
time that targeting specifically inflammation is useful for patients
with atherosclerosis (Ridker et al., 2017).
More than 10,000 patients with a previous history of MI
and levels of hs-CRP >2 mg/L were randomly assigned to
three different dosages of canakinumab, an antibody which
binds and blocks selectively the IL-1beta receptor (no effect
observed for IL-1alpha). A control placebo group was included
in the study. Due to financial considerations, the final sample
size was reduced but the follow-up was extended. Interestingly
the primary endpoint was reached in significantly less patients
assigned to canakinumab then placebo. On the other hand, more
deaths from infections were detected in the canakinumab group
(Ridker et al., 2017).
Thus, a definitive point for the inflammatory hypothesis has
been finally reached: atherosclerosis is an inflammatory disease
which can be targeted by a specific anti-inflammatory therapy.
But the drug to use remains still undefined. In fact, at least for
canakinumab, there are simple considerations which will limit its
widespread use: first the weight of the increase of deaths from
infections may counterbalance the decrease in CV events; second
the price of this therapy is still not easily affordable (Harrington,
2017).
Clinical trials to test a cheaper anti-inflammatory drug for
atherosclerosis, the MTX, are still ongoing (Everett et al., 2013;
Moreira et al., 2013).
Anti-inflammatory targets are probably multiplex and
many drugs could target different steps in the inflammatory
process. In this regard, many genetic studies and especially
genome wide association studies (GWAS) have pinpointed
new molecular candidates that might represent specific targets
for the inflammatory process in atherosclerosis rather than
other inflammatory disease. Thus, genetics could be one of the
key to detect molecular targets which specifically address CV
inflammation. By searching in the Pubmed database, on the
15th of November 2017 and using as key words: “genome wide
association study” OR “coronary” AND “atherosclerosis,” 2,858
citations were retrieved. In the remaining of the review, we
focus our attention on some interesting examples between the
screened studies where inflammatory loci were identified by the
genome wide strategy to support the inflammatory hypothesis.
Even if we acknowledge that our search is not exhaustive, since it
is not a systematic review, we have found and reported beyond
some significant examples of genes and SNPs in inflammatory
loci potentially implicated in coronary disease.
GENETIC VARIANTS IN INFLAMMATORY
GENES AND CORONARY ARTERY
DISEASE (CAD)
Regarding genes involved in inflammatory pathway, C-X-C
motif ligand 12 (CXCL12), SH2B adaptor protein 3 (SH2B3),
AB0, Human Leukocyte Antigen (HLA), interleukin 6 receptor
(IL-6R), IL-5, Platelet endothelial cell adhesion molecule 1
(PECAM1), Protein C Receptor (PROCR) and antisense non-
coding RNA in the INK4 locus (ANRIL) have been identified
in different GWAS and sometimes confirmed in case-controls
studies as significantly associated to coronary artery disease
(CAD) (Table 1).
CXCL12 Polymorphisms
CXCL12 is a gene located on 10q11.1 encoding for a member
of the alpha chemokine protein family, also called stromal
cell-derived factor-1 (SDF-1). It is involved in vascular repair
and remodeling through endothelial progenitor cell recruitment,
and it is expressed in atherosclerotic lesion by contributing to
macrophages migration that promote formation of complicated
and unstable plaques by maintaining a pro-inflammatory
microenvironment (Farouk et al., 2010).
The association between two SNPs (rs501120 and rs1746048)
on 10q11.21 and CAD has been originally shown in the GWAS
performed in the Wellcome Trust Case Control Consortium
Study (WTCCC) involving 1,926 CAD patients and 2,938
controls (Burton et al., 2007) but not emphasized. In fact, both
rs501120 [per allele odds ratio (OR) 1.24] and rs1746048 (OR
1.21) resulted associated with CAD but not at a genome wide
significant level (Burton et al., 2007). In the same year, data of the
Wellcome Trust Case Control Consortium and of the German
Myocardial Infarction Family Study (enrolling 875 MI patients
lower than 60 years and 1,644 healthy controls) were combined
and confirmed previously published results (Samani et al., 2007)
about these SNPs.
Kathiresan et al. published the results of a GWAS conducted
in 2,967 early-onset MI cases (men ≤50 years and women ≤60
years) and in 3,075 age- and sex-matched controls enrolled in the
Myocardial Infarction Genetics Consortium (MIGen), other than
in an additional 6 studies comprising in total 5,469 MI cases and
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TABLE 1 | Single nucleotide polymorphisms in inflammatory gene related to CAD.
Locus Gene(s) Polymorphism(s)
and association
Population(s) References
1 IL6R rs4845625 (intron)
P = 3.64 × 10−10
CARDIoGRAMplusC4D Consortium
(n = 63,746 CAD patients; n = 130,681 HC)
CARDIoGRAMplusC4D
Consortium et al., 2013
5q31.1 IL-5 rs2706399 (near gene)
P = 2.1 × 10−6 (combined)
IBC 50K CAD Consortium
Discovery:
(n = 15,596 European and South Asian CAD patients; n = 34,992
European and South Asian HC)
Replication:
(n = 17,121 CAD patients; n = 40,473 HC)
IBC 50K CAD
Consortium, 2011
6p21.3 HLA-C
HLA-B
HCG27
rs3869109 (near gene)
P = 1.12 × 10−9 (combined)
Discovery:
5 European case control meta-analysis (OHGS_A, OHGS_CCGB_B,
DUKE, WTCCC, ITH)
(n = 7,123 CAD patients; n = 6,826 HC)
Replication:
5 CAD European case control studies (GerMIFS1, GerMIFS2,
PennCath, MedStar, OHGS_CCGB_S)
(n = 5,211 CAD patients; n = 5,821 HC)
Davies et al., 2012
6p21.3 HLA-C
HLA-B
HCG27
rs3869109 (near gene)
P < 0.05
Chinese Han population
(n = 422 patients including 210 cases with coronary stenosis ≥50% or
previous MI; n = 212 HC)
Xie et al., 2013
9p21.3 ANRIL rs1333049 (near gene)
1.8 × 10−14
Wellcome Trust Case Control Consortium (WTCCC)
(n = 1,926 CAD patients; n = 2,938 HC)
Burton et al., 2007
9p21.3 ANRIL rs1333049 (near gene)
P = 1.80 × 10−14 for WTCCC
P = 3.40 × 10−6 for German
study
WTCCC study
(n = 1,988 MI patients or coronary revascularization <66 years;
n = 3,004 HC)
German study
(n = 875 MI patients <60 years; n = 1,644 HC)
Samani et al., 2007
9p21 ANRIL rs2383207 (intron variant)
P = 2.0 × 10−16 (combined)
rs10757278 (near gene)
P = 1.2 × 10−20 (combined)
Iceland A (n = 1,607 MI patients; n = 6,728 HC)
Iceland B (n = 665 MI patients; n = 3,533 HC)
Atlanta (n = 596 MI patients; n = 1,284 HC)
Philadelphia (n = 582 MI patients; n = 504 HC)
Durham (n = 1137 MI patients; n = 718 HC)
All groups (n = 4,587 MI patients / n = 12,767)
Helgadottir et al., 2007
9p21 ANRIL rs10757274 (near gene)
P = 3.9 × 10−6 (combined)
rs2383206 (intron variant)
P = 3.9 × 10−6 (combined)
Copenhagen City Heart Study (CCHS) (n = 1,525 CHD patients;
n = 9,053 HC)
Dallas Heart Study (DHS) (n = 154 CHD patients; n = 527 HC)
Ottawa Heart Study population (OHS-3) (n = 647 CHD patients;
n = 847 HC)
McPherson et al., 2007
9p21.3 ANRIL rs10965215 (intron variant)
P = 0.020
rs10738605 (nc transcript
variant)
P = 0.019
Chinese Han population
(n = 286 MI patients; n = 646 HC)
Cheng et al., 2017
9q34.2 AB0 rs579459 (near gene)
P = 4.08 × 10−14 (combined)
14 GWAS
Discovery:
(n = 22,233 CAD patients; n = 64,762 European HC)
Replication:
(n = 30,949 CAD patients; n = 27,674 HC)
Schunkert et al., 2011
9q34.2 AB0 rs514659 (near gene)
P = 7.62 × 10−9
and other 8 SNPs at genome
wide significant level
n = 5,783 patients who had angiographic CAD and MI;
n = 3,644 patients who had angiographic CAD but no MI
Reilly et al., 2011
9q34.2 AB0 rs579459 (near gene)
P = 2.66 × 10−8
CARDIoGRAMplusC4D Consortium
(n = 63,746 CAD patients; n = 130,681 HC)
CARDIoGRAMplusC4D
Consortium et al., 2013
10q11.21 CXCL12 rs501120 (near gene)
P = 1.31 × 10−3 (combined)
rs1746048 (near gene)
P = 2.96 × 10−3 (combined)
WTCCC study
(n = 1,926 MI patients or coronary revascularization <66 years;
n = 2,938 HC)
Burton et al., 2007
(Continued)
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TABLE 1 | Continued
Locus Gene(s) Polymorphism(s)
and association
Population(s) References
10q11.21 CXCL12 rs1746048 (near gene)
P = 5.73 × 10−7 (combined)
rs501120 (near gene)
P = 9.46 × 10−8
(combined)
WTCCC study
(n = 1,988 MI patients or coronary revascularization <66 years;
n = 3,004 HC)
German study
(n = 875 MI patients <60 years; n = 1,644 HC)
Samani et al., 2007
10q11.21 CXCL12 rs1746048 (near gene)
P = 8.14 × 10−11
(combined)
Discovery:
MIGen (n = 2,967 early-onset MI cases (men ≤50 years and women
≤60 years); n = 3,075 HC)
Replication:
6 other studies (n = 5,469 MI patients; n = 5,469 HC)
Kathiresan et al., 2009
10q11.21 CXCL12 rs501120 (near gene)
P = 4.34 × 10−4 (combined)
Coronary Artery Disease Consortium
(n = 11,550 CAD patients; n = 11,205 HC)
Coronary Artery
Disease Consortium
et al., 2009
10q11.21 CXCL12 rs501120 (near gene)
P = ns(combined)
Only women: P = 8.36 × 10−3
Chinese Han population
(n = 2,335 CAD patients; n = 1,078 HC)
Xie et al., 2011
10q11.21 CXCL12 rs1065297 (3′ UTR)
all P = 0.01;
Chinese Han population
(n = 597 CAD patients; 685 HC)
Zhang et al., 2017
12q24 SH2B3 rs3184504 (Trp60Arg)
P = 8.6 × 10−8
Six populations
(n = 6,650 MI patients; n = 40,621 HC)
Gudbjartsson et al.,
2009
12q24 SH2B3 rs3184504 (Trp60Arg)
P = ns
FGENTCARD population
(n = 1520 CAD patients; n = 424 HC)
Saade et al., 2011
12q24 SH2B3 rs3184504 (Trp60Arg)
P = 5.44 × 10−11
CARDIoGRAMplusC4D Consortium
(n = 63,746 CAD patients; n = 130,681 HC)
CARDIoGRAMplusC4D
Consortium et al., 2013
12q24 SH2B3 rs653178 (intron variant)
P = 2.2 × 10−6
CARDIoGRAM
(n = 52,120 MI patients; n = 34,875 HC)
Olden et al., 2013
12q24 SH2B3 rs79105258 (near gene)
P = 2.5 × 10−5
TAICHI Consortium
(n = 3,133 Taiwan CAD patients; n = 5,423 HC)
Assimes et al., 2016
17 PECAM1 rs1867624 (near gene)
P = 3.98 × 10−8
CARDIoGRAMplusC4D, EPIC-CVD, + 8 other studies and six studies
from the Myocardial Infarction Genetics Consortium (MIGen)
(n = 88,192 CAD patients; n = 162,544 HC)
Howson et al., 2017
20 PROCR rs867186 (Ser219Gly)
P = 2.70 × 10−9
CARDIoGRAMplusC4D, EPIC-CVD, + 8 other studies and six studies
from the Myocardial Infarction Genetics Consortium (MIGen)
(n = 88,192 CAD patients; n = 162,544 HC)
Howson et al., 2017
ANRIL, antisense non-coding RNA in the INK4 locus; CAD, coronary artery disease; CXCL12, C-X-C motif ligand 12; HC, healthy controls; HLA, Human Leukocyte Antigen; IL-5,
interleukin 5; IL-6R, interleukin 6 receptor; MI, myocardial infarction; PECAM1, Platelet endothelial cell adhesion molecule 1; PROCR, Protein C Receptor; SH2B3, SH2B adaptor
protein 3.
5,469 controls (Kathiresan et al., 2009). The association between
rs1746048 of the CXCL12 gene andMI resulted highly significant
(combined p-value 8.14× 10−11).
By analyzing 11,550 cases and 11,205 controls from 9
European studies, the Coronary Artery Disease Consortium
reported for the SNP rs501120 a nominally significant association
(P = 4.34 × 10−4) and observed a possible sex interaction with
a significant effect in women (OR = 1.29, 95% CI: 1.15–1.45,
P = 1.86× 10−5) but not in men (OR= 1.03, 95% CI: 0.96–1.11,
P = 0.387; Coronary Artery Disease Consortium et al., 2009).
Successively, this observation has been replicated in a
Chinese Han population of 2,335 coronary atherosclerosis
patients and 1,078 controls undergoing coronary angiography.
Accordingly, rs501120 at 10q11.21 was associated with coronary
atherosclerosis in females (P= 8.36× 10−3) but not inmales (Xie
et al., 2011).
In the same year, it was shown that SNPs rs1746048 and
rs501120 of the CXCL12 gene, are associated with high CXCL12
mRNAs and high CXCL12 plasma levels (Mehta et al., 2011)
suggesting their functionality.
Very recently, in a case-control study involving 597 Chinese
Han CAD patients and 685 healthy control, Zhang et al., by
genotyping six SNPs (rs1065297, rs1801157, rs266089, rs197452,
rs2839693, and rs10793538), identified three different SNPs
(rs1065297, rs266089, and rs10793538) of CXCL12 associated
with the risk of CAD (Zhang et al., 2017). Stratified according
to gender, in the allele model, rs266089 and rs2839693 in
CXCL12 gene were associated with the risk of CAD in
men, while rs1065297 and rs10793538 in CXCL12 gene were
associated with the risk of CAD in women. However, after
adjustment by sex and age this association resulted not yet
significant.
Anyhow, although this gene appears to be quite interesting,
most of the tested SNPs are not functional, and the conflicting
results obtained prompt to be cautious about a solid implication
of this gene in coronary atherosclerosis.
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SH2B3 Polymorphisms
SH2B3, also known as LNK, encodes for an intracellular adaptor
protein expressed in vascular endothelial cells and functions as
a negative regulator in many pathways, as cytokine signaling
pathways (Fitau et al., 2006; Gueller et al., 2011). In a mouse
model of atherosclerosis, it has been demonstrated that this gene
is up-regulated over five-fold as endothelial cells change from
normal to the atherosclerotic disease state (Erbilgin et al., 2013).
Gudbjartsson et al., by investigating sequence variants
affecting eosinophil counts in blood of 9,392 Icelanders and
in six different populations (6,650 cases and 40,621 controls)
found that the SNP rs3184504 (R262W) in exon 3 of SH2B3
located at 12q24, resulted significantly associated with MI
(Gudbjartsson et al., 2009). Since eosinophils are leukocytes
involved in initiation and propagation of inflammatory
responses, the accumulation of eosinophils in the thrombus
could contribute to the genesis and progression of thrombus
(Jiang et al., 2015).
Saade et al. performed a replication study of nine previously
identified CAD/MI susceptibility loci in a total of 2,002
subjects of the FGENTCARD population (Saade et al., 2011).
Previously reported results about rs3184504 and rs653178 were
not confirmed in this population.
The SNP rs653178 near SH2B3 showed, in a very large
population including participants from the CARDIoGRAM
(n= 86,995) and the ICBP (n= 69,395), a significant association
with CAD (P = 2.2× 10−6; Olden et al., 2013).
With the aim to investigate the genetic susceptibility to
CAD, in a large study (63,746 CAD cases and 130,681
controls) performed by combining genome-wide data from the
CARDIoGRAM and C4D consortia, Deloukas and colleagues
found evidence that only the SNP rs3184504 at the SH2B3
locus displayed statistically significant association with CAD
(CARDIoGRAMplusC4D Consortium et al., 2013).
Different results were more recently reported by Assimes et al.
by genotyping 5,423 HC and 3,133 CAD patients from Taiwan
(Assimes et al., 2016). Despite the association of rs79105258
(P = 2.5 × 10−5), it was observed that the rs79105258 of the
SH2B3 contributes to CAD only in the presence of the rs2289800
of COL4A1.
Ji et al. conducted a study on a Chinese Han population of
456 CAD patients (291 men, 165 women) and 685 age-matched
controls (385 men, 300 women) to determine the influence of
sex on the association between SH2B3 polymorphisms and CAD.
Despite SH2B3 polymorphisms resulted associated with CAD
susceptibility in both women and men (Ji et al., 2017), the
authors observed that the SH2B3 haplotypes were associated with
decreased CAD risk in women (P = 0.007) but increased CAD
risk in men (P = 0.047). Interestingly enough, the rs3184504
at the SH2B3 locus is one of the 29 SNPs identified in the first
consortium able to discover genetic loci consistently associated
with BP/hypertension at a genome significant level depicting a
possible link between hypertension and atherosclerosis (Ehret
et al., 2011).
Also for this gene the first findings were not constantly
replicated but, differently from CXCL12, at least the rs3184504
determines an amino acid change and is located inside the gene.
Even if more research is needed, it sounds also attracting the
common positivity in GWAS for hypertension.
HLA Polymorphisms
HLA is a set of cell surface proteins essential for the acquired
immune system by playing an important role in inflammation
and T cell responses and mediating the interactions between
leucocytes.
An association between a HLA locus, 6p21.3, and CHD was
demonstrated for the first time by a meta-analysis of 5 GWAS
including 13,949 subjects of European ethnicity (7,123 cases,
6,826 control subjects). The SNP significantly associated with
CAD, the rs3869109, was located in an intragenic region between
HLA-C andHCG27 (HLA complex group 27; Davies et al., 2012).
To investigate whether this SNP confers the risk of premature
CAD in the Chinese Han population, this association was
explored in a total of 422 patients including 210 cases with
coronary stenosis ≥50% or previous MI (male <55 years and
female <65 years) and 212 controls without documented CAD
(Xie et al., 2013). The authors showed that rs3869109 G-carriers
have a higher risk of premature CAD than AA homozygotes (OR:
1.997, 95% CI: 1.166–3.419, P = 0.012; OR 1.695, 95% CI: 1.044–
2.752, P = 0.033; respectively) and that there was a significant
association between rs3869109 genotypes and the severity of
disease.
Sinisalo et al. by conducting a large-scale genetic analysis
on a case-control cohort comprising 5,376 ACS cases and
4,852 unrelated controls from 4 populations of 2 European
countries, found a risk haplotype for the disease containing single
nucleotide polymorphisms from BTNL2 and HLA-DRA genes
and the HLA-DRB1∗01 allele (Sinisalo et al., 2016).
Taking together, the results of these studies are not convincing
about a pivotal role of HLA in atherosclerosis.
ABO
Among the 13 loci newly associated with CAD (P<5×10−8)
in the very large meta-analysis performed by Schunkert et al.
in 14 GWAS comprising 22,233 CAD patients and 64,762
controls of European descent followed by genotyping of 56,682
additional individuals (Schunkert et al., 2011), the risk allele
on chromosome 9q34.2 (rs579459) in the ABO gene resulted
associated with CAD (P = 4.08 × 10−14) and weakly with
increased LDL (P = 0.0049) and total cholesterol (P = 0.0038).
To identify loci that predispose to MI, Reilly et al. compared
in a GWAS 5,783 patients who had angiographic CAD and
MI and 3,644 patients who had angiographic CAD but no
MI. They identified a novel association at the ABO locus:
11 ABO SNPs resulted significantly related to MI risk (Reilly
et al., 2011). The authors hypothesized that the AB0 association
could be attributable to the glycotransferase-deficient enzyme
that encodes the AB0 blood group 0 phenotype previously
proposed to protect against MI (Reilly et al., 2011). It has
been hypothesized that blood group antigens could be directly
involved in atherosclerotic inflammatory process (Wu et al.,
2007). The same considerations as for the HLA locus apply also
to the ABO locus.
Frontiers in Pharmacology | www.frontiersin.org 6 February 2018 | Volume 9 | Article 55
Fava and Montagnana Atherosclerosis, Inflammation, and Genetics
Other “Inflammatory” Loci Associated with
CAD
In 2007 the locus 9p21 was identified as the strongest genetic
susceptibility locus for CAD and MI independently by three
different research groups (Burton et al., 2007; Helgadottir et al.,
2007; McPherson et al., 2007; Samani et al., 2007). One year
later, Schunkert confirmed the association between chromosome
9p21.3 and CAD in 7 case-control studies involving 4,645
patients and 5,177 healthy controls (Schunkert et al., 2008).
The variants identified in these studies are located in a
locus that contains several genes, like CDKN2A [coding for
p16(ink4a) and p14(ARF)], CDKN2B [coding for p15(ink4b)],
MTAP (Holdt et al., 2011). These proteins are cyclin-dependent
kinase inhibitors involved in the regulation of cell proliferation,
aging, senescence and apoptosis in many cell types and result
abundantly expressed in atherosclerotic lesions (Holdt et al.,
2011). In this locus also the gene antisense non-coding RNA in
the INK4 locus (ANRIL) maps also called the CDKN2B antisense
RNA 1.
Several SNPs in the 9p21.3 locus have been showed associated
with CAD risk (Burton et al., 2007; Samani et al., 2007; Schunkert
et al., 2011).
More recently, a consistent association between two variants
in the 9p21.3 locus (rs10965215 and rs10738605) and CAD has
been reported also in the Chinese Han population (Cheng et al.,
2017). For rs10965215, unconditional logistic regression analysis
revealed that the G allele increased MI risk with OR of 1.37
(95% CI = 1.05–1.78, P = 0.020). For rs10738605, C allele
conferred increased MI risk with OR of 1.38 (95% CI = 1.06–
1.80, P = 0.019) as compared to the G allele after adjustment for
conventional risk factors (Cheng et al., 2017).
ANRIL is expressed in endothelial cells, smooth muscle
cells, and inflammatory cells and is involved in the regulation
of expression of adjacent protein coding genes, including
MTAP, CDKN2A (p15INK4b), and CDKN2B (p16INK4a)
through multiple mechanisms, including RNA interference, gene
silencing, chromatin remodeling, or DNA methylation (Holdt
et al., 2010).
This locus remains still one of the most promising for
coronary atherosclerosis, being detected in most of the GWAS
performed and subtending genes of putative effect. Nevertheless,
the exact mechanism and the gene responsible is to be definitely
proved.
The IBC 50K CAD Consortium examined 49,094 genetic
variants in 2,100 genes in 15,596 CAD cases and 34,992 controls
and replicate putative novel associations in an additional 17,121
CAD cases and 40,473 controls (IBC 50K CAD Consortium,
2011). Among the new variants identified, SNP (rs2706399) in
interleukin 5 (IL5) gene (5q31.1) resulted statistically associated
with CAD in the discovery and replication study (combined
p-value 2.1× 10−6). IL5 is an interleukin produced by T helper-2
cells with a role in the inflammatory process characterizing
the development and progression of atherosclerosis and CAD
(Hansson, 2005).
The association between rs4845625 of the IL6R
and CAD (P = 3.64 × 10−10) was demonstrated in
the CARDIoGRAMplusC4D Consortium, in which the
CARDIoGRAM population (22,233 cases and 64,762 controls)
was expanded with 34 additional European or south Asian
population comprising 41,513 cases and 65,919 controls
(CARDIoGRAMplusC4D Consortium et al., 2013). The
IL6-mediated activation of IL6R, a receptor located on
the leukocytes and hepatocytes membrane, stimulates the
proinflammatory cascade including hepatic production of
acute phase reactants C-reactive protein and fibrinogen
(Schuett et al., 2009).
Moreover, the Asp358Ala (rs2228145) in IL6R was not
associated with several traditional risk factors such as blood
pressure, adiposity, hyperglycaemia, cholesterol, and smoking
but with the concentration IL-6, C-reactive protein, fibrinogen,
and coronary heart disease implying a causal role for this
inflammatory pathway (IL6R Genetics Consortium Emerging
Risk Factors Collaboration et al., 2012).
Howson et al. genotyped 56,309 participants and performed
meta-analysis of results with 194,427 participants previously
genotyped, totalising 88,192 CAD cases and 162,544 controls.
The authors identified 25 new SNP–CAD associations
(P<5×10−8) from 15 genomic regions, including SNPs in
PECAM1 (rs1867624, P = 3.98 × 10−8) and in PROCR
(rs867186, P = 2.70 × 10−9) genes, that are involved in cellular
adhesion, leukocyte migration and inflammation (Howson et al.,
2017).
In particular PECAM-1 is important to maintain the integrity
of the vascular barrier. Accordingly, the consequence of a
not conserved barrier can be the development of chronic
inflammatory diseases such as atherosclerosis (Privratsky et al.,
2011).
These are a few examples of how genetics can and will be able
to in the near future identify molecules or pathways as tailored
anti-inflammatory therapeutic targets in atherosclerosis.
CONCLUSION
Despite the inflammatory core of atherosclerosis has
been well described, a straightforward anti-inflammatory
therapy for targeting inflammation is still missing in
the physician’s armamentarium. Therapy with biological
drugs is attractive but probably too expensive to be
largely available. Newer targets are needed and genetics
can help with this issue. So far, the results coming from
GWAS have pinpointed a few loci closed to inflammatory
molecules and/or pathways consistently associated with
atherosclerosis and CV events, revamping the strict link between
inflammation and atherosclerosis suggesting some tailored target
therapy.
In some cases Mendelian randomization studies can help in
detecting which of them is a real primary therapeutic goal and
which should be considered secondary (Ridker and Lüscher,
2014).
In the upcoming genomic era, both whole-exome and
whole-genome sequencing will pinpoint new and old loci
associated with atherosclerosis identifying new molecular targets
or characterizing which inflammatory pathway could be a
suitable target to block atherosclerosis even in its early stages.
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